worldwid
outbreak
swineorigin
influenza
viru
iav
increas
number
influenza
case
caus
highli
pathogen
avian
influenza
hpai
acceler
need
develop
vaccin
antivir
agent
iav
among
variou
antivir
neutral
monoclon
antibodi
mab
consid
import
passiv
therapeut
immedi
effect
viral
pathogen
report
pseudoviru
neutral
assay
rapid
screen
neutral
mab
target
hemagglutinin
ha
iav
studi
gener
six
pseudovirus
backbon
respect
express
ha
four
clade
iav
epidem
iav
result
pseudovirus
abl
infect
varieti
human
nonhuman
cell
cell
human
kidney
suscept
target
cell
use
establish
pseudoviru
neutral
assay
show
three
ten
select
mab
specif
ha
could
potent
neutral
infect
pseudoviru
bear
ha
homolog
iav
strain
highli
consist
result
microneutr
assay
test
strain
live
iav
sinc
pseudoviru
neutral
assay
involv
infecti
viru
perform
without
requir
laboratori
may
appli
safe
rapid
screen
neutral
mab
antivir
agent
target
ha
iav
worldwid
outbreak
swineorigin
influenza
viru
iav
pose
increas
threat
futur
influenza
epidem
potenti
induc
highli
pathogen
avian
influenza
hpai
viru
sinc
reemerg
iav
caus
death
among
total
confirm
case
may
http
wwwwhointcsrdiseas
highlight
signific
develop
vaccin
antivir
agent
diverg
iav
among
structur
protein
influenza
virus
hemagglutinin
ha
play
import
role
viral
bind
receptor
viru
entri
membran
fusion
viru
infect
ha
first
mediat
viru
attach
subsequ
entri
target
cell
thu
ha
protein
consid
primari
target
induc
protect
immun
iav
inde
antibodi
specif
ha
shown
inhibit
andor
neutral
viru
infect
vaccin
host
antiha
monoclon
antibodi
mab
regard
one
import
passiv
therapeut
treatment
influenza
also
shown
mab
target
ha
glycoprotein
may
broadli
neutral
homolog
heterolog
strain
differ
clade
iav
infect
prevent
format
escap
mutant
identifi
potent
specif
neutral
mab
immunotherapeut
treatment
influenza
essenti
develop
assay
rapid
screen
neutral
mab
ha
iav
current
microneutr
plaqu
reduct
assay
mainli
use
evalu
neutral
activ
antibodi
howev
infecti
replicationcompet
live
iav
biosafeti
level
facil
gener
requir
perform
assay
report
develop
safe
conveni
neutral
assay
rapid
screen
neutral
mab
target
ha
iav
first
gener
seri
pseudovirus
bear
four
clade
iav
isol
avian
human
respect
epidem
iav
backbon
pseudovirus
singlecycl
replicationdefici
virus
use
pseudovirus
establish
neutral
assay
laboratori
base
screen
panel
mab
specif
ha
viru
success
identifi
three
specif
neutral
mab
suggest
establish
assay
safe
effici
screen
neutral
mab
target
ha
iav
tabl
synthes
integr
dna
technolog
coralvil
ia
insert
vector
construct
recombin
plasmid
contain
ha
respect
design
qhha
xjha
ahha
confirm
correct
insert
sequenc
analysi
gener
influenza
pseudoviru
done
previous
describ
modif
briefli
cell
atcc
manassa
va
cotransfect
lg
plasmid
encod
envdefect
luciferaseexpress
lg
plasmid
includ
qhha
xjha
ahha
respect
cultur
dish
use
calcium
phosphat
method
cell
chang
fresh
dmem
h
later
exogen
bacteri
neuraminidas
na
vibrio
cholera
sigma
st
loui
mo
ad
concentr
lgml
h
posttransfect
transfect
without
ad
na
use
parallel
control
supernat
contain
ha
pseudoviru
without
na
harvest
h
posttransfect
use
singlecycl
infect
viral
particl
correspond
ha
name
qhha
xjha
ahha
hkha
pseudovirus
respect
tabl
plasmid
encod
vesicular
stomat
viru
g
protein
vsvg
vector
use
cotransfect
plasmid
gener
vsvg
pseudoviru
pseudoviru
without
env
control
titrat
pseudoviru
cell
infect
pseudoviru
dilut
cultur
plate
follow
detect
luciferas
activ
h
later
titer
pseudoviru
express
rel
luciferas
unit
rlu
produc
pseudoviru
measur
elisa
briefli
elisa
plate
precoat
clone
nih
lgml
overnight
block
nonfat
milk
h
lyse
pseudovirus
ad
plate
incub
h
wash
hivigg
sera
ad
lgml
incub
h
follow
sequenti
incub
biotinlabel
goat
antihuman
igg
streptavidinconjug
horseradish
peroxidas
hrp
h
substrat
tetramethylbenzidin
tmb
zyme
carlsbad
ca
ad
plate
reaction
stop
n
h
absorb
nm
measur
elisa
plate
reader
tecan
san
jose
ca
viral
core
ha
surfac
gener
pseudovirus
determin
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
sdspage
follow
western
blot
accord
previou
protocol
modif
briefli
lyse
pseudovirus
resolv
tricin
gel
invitrogen
transfer
nitrocellulos
membran
biorad
laboratori
hercul
ca
block
nonfat
milk
overnight
blot
respect
incub
clone
nih
antiha
mab
produc
dilut
three
wash
blot
incub
hrpconjug
goat
antimous
igg
zyme
h
room
temperatur
signal
visual
ecl
western
blot
substrat
reagent
amersham
hyperfilm
ge
healthcar
piscataway
nj
detect
cell
tropism
cellswel
madindarbi
canin
kidney
mdck
chines
hamster
ovari
vero
cell
atcc
respect
transduc
produc
pseudovirus
fresh
dmem
ad
h
later
luciferas
activ
detect
h
posttransduct
express
rlu
gene
encod
fulllength
ha
iav
plu
tag
amplifi
pcr
insert
baculoviru
transfer
vector
bd
bioscienc
san
jose
ca
construct
rhabacul
plasmid
express
rha
protein
conduct
accord
manufactur
protocol
previous
describ
method
briefli
lg
rhabacul
plasmid
mix
lg
bd
baculogold
linear
baculoviru
dna
sit
room
temperatur
min
addit
ml
bd
baculogold
transfect
buffer
b
mixtur
ad
insect
cell
atcc
precov
ml
transfect
buffer
follow
incub
cell
h
cultur
cell
fresh
ii
sfm
invitrogen
day
supernat
collect
infect
cell
three
cycl
viru
amplif
cell
cultur
supernat
cycl
collect
purif
rha
protein
use
column
promega
madison
wi
five
femal
balbc
mice
age
week
subcutan
vaccin
purifi
rha
protein
lgmous
presenc
freund
complet
adjuv
fca
sigma
boost
twice
immunogen
lgmous
contain
freund
incomplet
adjuv
fia
sigma
interv
hybridoma
techniqu
gener
screen
specif
mab
ha
protein
perform
accord
standard
protocol
briefli
vaccin
mice
sacrif
day
last
boost
splenocyt
fuse
mous
myeloma
cell
haspecif
mabscreen
posit
hybridoma
screen
elisa
use
rha
protein
coat
antigen
posit
cell
expand
retest
subclon
gener
stabl
hybridoma
cell
line
mab
purifi
cultur
supernat
use
nprotein
sepharos
fast
flow
ge
healthcar
neutral
activ
mab
infect
ha
pseudoviru
perform
follow
briefli
pseudoviruscontain
supernat
incub
serial
dilut
ha
mab
h
ad
cell
preplat
cultur
plate
well
mab
sever
acut
respiratori
syndrom
coronaviru
sar
use
neg
control
twentyfour
hour
later
cell
refe
fresh
medium
follow
lyse
cell
h
later
use
cell
lysi
buffer
promega
transfer
lysat
luminomet
plate
luciferas
substrat
promega
ad
plate
rel
luciferas
activ
determin
ultra
luminomet
tecan
neutral
ha
pseudoviru
calcul
present
neutral
antibodi
titer
nt
titer
antiinfluenza
ha
neutral
activ
mab
determin
microneutr
assay
follow
briefli
serial
dilut
mab
mix
avietnam
incub
h
ad
mdck
cell
quadrupl
medium
replac
fresh
dmem
h
later
cell
cultur
continu
h
viral
cytopath
effect
cpe
observ
daili
record
day
postinfect
neutral
antibodi
titer
nt
determin
ha
test
defin
lowest
dilut
neg
ha
cell
cultur
supernat
incub
equal
volum
turkey
red
blood
cell
lampir
biolog
laboratori
pipersvil
pa
room
temperatur
min
valu
present
mean
standard
deviat
sd
statist
signific
among
differ
group
calcul
student
test
use
stata
statist
softwar
p
valu
less
consid
signific
verifi
whether
ha
pseudovirus
contain
first
use
elisa
detect
pseudoviruscontain
supernat
six
ha
pseudovirus
one
vsvg
pseudoviru
one
pseudoviru
contain
ng
ml
hiv
western
blot
detect
reactiv
ha
pseudoviru
mab
specif
iav
ha
respect
shown
fig
clear
band
respect
correspond
ha
observ
six
ha
pseudovirus
suggest
ha
influenza
pseudoviru
incorpor
viral
particl
exogen
na
ad
cell
h
posttransfect
compar
transduct
activ
pseudoviru
absenc
presenc
na
fig
indic
ha
pseudoviru
contain
na
induc
significantli
higher
level
infect
averag
increas
rlu
contrast
pseudoviru
without
na
transduc
cell
highest
infect
reach
qhha
pseudoviru
express
ha
highli
pathogen
iav
goos
tabl
sinc
ha
pseudovirus
contain
na
may
abl
improv
infect
rate
significantli
use
subsequ
experi
detect
pseudoviru
cell
tropism
test
neutraliz
activ
ha
mab
detect
cell
tropism
produc
ha
pseudoviru
cell
variou
tissu
differ
host
includ
mdck
dog
kidney
human
lung
chines
hamster
ovari
vero
african
green
monkey
kidney
human
kidney
cell
respect
transduc
six
pseudovirus
contain
ngml
luciferas
activ
detect
h
postinfect
vsvg
pseudoviru
broad
host
rang
capabl
infect
multipl
tissu
variou
host
pseudoviru
use
posit
neg
control
shown
fig
infect
mdck
cell
rel
higher
vero
cell
particularli
pseudovirus
demonstr
significantli
higher
level
infect
abil
cell
cell
suggest
cell
deriv
human
kidney
may
suscept
deriv
human
tissu
nonhuman
host
ha
pseudoviru
infect
addit
avian
goos
origin
pseudoviru
qhha
show
higher
affin
infect
humanhost
pseudovirus
xjha
ahha
hkha
expect
posit
control
vsvg
pseudoviru
abl
infect
test
cell
line
neg
control
pseudoviru
unabl
infect
cell
line
elisa
use
initi
screen
mab
gener
immun
mice
rha
shown
fig
mab
initi
screen
haspecif
antibodi
respons
highest
antibodi
titer
select
detect
neutral
activ
five
pseudovirus
express
ha
iav
qhha
xjha
ahha
hkha
one
pseudoviru
bear
ha
epidem
iav
tabl
vsvg
pseudoviru
cell
sinc
cell
line
demonstr
highest
abil
support
viru
infect
shown
fig
among
select
mab
specif
ha
mab
particularli
mab
neutral
homolog
strain
pseudotyp
viru
infect
haspecif
mab
show
nonneutr
activ
homolog
heterolog
qhha
xjha
ahha
hkha
epidem
pseudovirus
well
vsvg
pseudoviru
addit
unrel
control
mab
specif
sarscov
spike
protein
could
neutral
pseudovirus
result
indic
establish
pseudoviru
neutral
assay
specif
ha
suggest
potenti
applic
quick
effect
screen
mab
target
ha
iav
select
mab
test
neutral
activ
wildtyp
viru
use
microneutr
assay
result
compar
pseudoviru
neutral
assay
base
homolog
viru
express
ha
tabl
show
mab
especi
mab
could
inhibit
infect
live
viru
mab
neutral
activ
viru
test
mdck
cell
sinc
result
correspond
pseudoviru
neutral
assay
base
ha
viru
type
establish
pseudoviru
neutral
assay
confirm
reliabl
method
test
neutral
activ
mab
ha
iav
studi
six
pseudovirus
produc
supernat
cell
presenc
absenc
exogen
na
respect
express
ha
varieti
four
clade
clade
hpai
viru
strain
epidem
strain
viru
isol
avian
goos
human
tabl
although
packag
ha
pseudovirus
without
na
may
infect
target
cell
addit
exogen
na
cell
cotransfect
ha
plasmid
shown
significantli
increas
transduct
effici
fig
possibl
na
protein
may
help
remov
sialic
acid
host
cell
facilit
viral
releas
thu
make
indispens
compon
habas
iav
infect
result
consist
previou
report
rong
colleagu
produc
ha
pseudovirus
demonstr
infect
number
nonhuman
mdck
vero
human
cell
human
cell
maintain
higher
transduct
efficaci
fig
reason
infer
avianorigin
swineorigin
virus
isol
avian
goos
human
higher
tendenc
infect
human
host
chines
hamster
african
green
monkey
result
highlight
import
develop
antiiav
agent
vaccin
treatment
prevent
influenza
pseudoviru
neutral
assay
develop
base
produc
ha
pseudovirus
use
screen
neutral
mab
ha
viru
three
ten
select
mab
abl
neutral
infect
pseudoviru
carri
ha
homolog
iav
none
neutral
pseudovirus
express
ha
heterolog
iav
unrel
vsvg
pseudoviru
test
cell
line
fig
result
highli
consist
microneutr
assay
tabl
find
demonstr
establish
pseudoviru
neutral
assay
highli
specif
sensit
thu
make
especi
suit
quick
screen
larg
amount
mab
short
period
time
compar
microneutr
assay
plaqu
reduct
neutral
assay
requir
handl
live
viru
use
approv
laboratori
facil
establish
noninfecti
virusbas
pseudoviru
neutral
assay
rel
safer
particularli
use
access
laboratori
restrict
neutral
antibodi
target
ha
iav
play
crucial
role
neutral
viru
infect
clear
viru
suppress
viru
spread
thu
applic
pseudoviru
neutral
assay
may
extend
evalu
efficaci
habas
influenza
vaccin
candid
antivir
agent
target
ha
iav
neutral
method
could
also
optim
detect
specif
neutral
activ
clinic
patient
sampl
may
use
predict
prognosi
diseas
conclud
ha
pseudovirusbas
neutral
assay
appli
screen
neutral
mab
therapeut
target
iav
ha
evalu
habas
iav
vaccin
well
detect
neutral
activ
clinic
sampl
make
possibl
assess
virusneutr
activ
safe
rapidli
without
use
live
infecti
influenza
virus
detect
limit
use
pseudoviru
neutral
assay
b
use
microneutr
assay
